The global microbiology testing market is expanding as healthcare facilities, pharmaceutical manufacturers, and research institutions invest in advanced microbial testing to support diagnostics, quality control, and antimicrobial resistance research. The market was valued at USD 5.77 billion in 2024 and is projected to reach USD 11.32 billion by 2035, growing at a CAGR of 6.32%.

The Microbiology Testing Market includes clinical diagnostics, pharmaceutical and biotechnology QC, food and beverage testing, cosmetic and personal care testing, environmental monitoring, reagents and consumables, instruments and equipment, software and services, culture-based testing, molecular diagnostics, mass spectrometry, and immunodiagnostics.

Hospitals and diagnostic laboratories hold a 56.1% share in 2025, processing hundreds of thousands of specimens daily across blood, respiratory, wound, and urine categories. High daily test volumes and automation budgets drive this segment.

Pharmaceutical and biotechnology companies represent a USD 1.15 billion segment in 2025, driven by regulatory QC compliance. EU Annex 1 and FDA cGMP mandates are creating upgrade pressure across contract manufacturing organizations.

Academic and research institutes are the fastest-growing end user, with a 13.4% CAGR from 2026 to 2035. This growth is fueled by government and philanthropic AMR research grants that reached USD 2.1 billion globally in 2024.

Food and cosmetic manufacturers are growing at a 10.4% CAGR, driven by supply-chain QC mandates. EU Cosmetics Regulation broadening and FSMA Preventive Controls Rule enforcement are key drivers.

The rising antimicrobial resistance burden is a major driver, with drug-resistant illnesses killing 1.27 million people in 2019 and potentially leading to 10 million deaths annually by 2050 if no action is taken. Governments across G7 and G20 nations have committed approximately USD 4.8 billion in AMR surveillance and stewardship financing between 2023 and 2025.

The future market will depend on rising antimicrobial resistance burden, laboratory automation and workforce shortages, tightening pharmaceutical and food-safety regulations, syndromic molecular panel adoption, and hospital infrastructure expansion in emerging economies.

FAQs

Q1. Why do hospitals dominate the end-user segment?
Hospitals process high volumes of specimens daily and invest in automation, driving significant demand for microbiology testing.

Q2. What is driving research institutes to adopt microbiology testing?
Government and philanthropic AMR research grants are driving research institutes to invest in advanced microbiology testing capabilities.

Tags: microbiology testing market, hospitals, pharmaceutical companies, research institutes, end users